Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer
Goubet,A.G., Lordello,L., Alves Costa Silva,C., Peguillet,I., Gazzano,M., Mbogning-Fonkou,M.D., Thelemaque,C., Lebacle,C., Thibault,C., Audenet,F., Pignot,G., Gravis,G., Helissey,C., Campedel,L., Roupret,M., Xylinas,E., Ouzaid,I., Dubuisson,A., Mazzenga,M., Flament,C., Ly,P., Marty,V., Signolle,N., Sauvat,A., Sbarrato,T., Filahi,M., Davin,C., Haddad,G., Bou Khalil,J., Bleriot,C., Danlos,F.X., Dunsmore,G., Mulder,K., Silvin,A., Raoult,T., Archambaud,B., Belhechmi,S., Gomperts Boneca,I., Cayet,N., Moya-Nilges,M., Mallet,A., Daillere,R., Rouleau,E., Radulescu,C., Allory,Y., Fieschi,J., Rouanne,M., Ginhoux,F., Le Teuff,G., Derosa,L., Marabelle,A., Van Dorp J., Van Dijk,N., van der Heijden,M.S., Besse,B., Andre,F., Merad,M., Kroemer,G., Scoazec,J.Y., Zitvogel,L., Loriot,Y.
Revue : Cancer Discov -
2022 /
8
Volume : 12
Pages : 2280-2307